The global Allergy Diagnostics And Therapeutics Market size was estimated at USD 58.31 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing incidences of allergic diseases, coupled with demand for advanced therapeutics, is expected to drive the market growth in the coming years. According to estimates published by the American Academy of Allergy Asthma & Immunology (AAAAI), allergic rhinitis affects approximately 10-30% of the global population, thereby impacting the adoption of allergy therapeutics globally.
The increasing integration of
technologically advanced products, such as the use of artificial intelligence
technology to advance treatment outcomes and manage diseases, helps
practitioners in the decision-making process. Furthermore, the rising adoption
of mHealth apps for diagnosing allergies such as rhinitis is expected to boost the
market. For instance, the MASK-Air app is dedicated specifically to allergic
rhinitis.
Monoclonal antibodies are anticipated to contribute to the development of new therapies
that eradicate specific allergy concerns, owing to their higher efficacy,
long-term tolerability, and safety. Hence, key companies are developing novel
& effective biologic-based therapies designed with target-specific
mechanisms directed toward selective targets, especially monoclonal antibodies.
In addition, consistent product approvals of highly significant monoclonal
antibodies for allergy disorders are anticipated to expand the scope for
growth.
New therapies such as anti-immunoglobulin E
(IgE) antibodies, cytokine modulators, and DNA vaccinations are being used to
treat allergic disorders. Omalizumab is a recombinant humanized IgG1 monoclonal
anti-IgE antibody, which is used for treating allergic chronic urticaria and
asthma. In April 2021, Genentech (Roche Group) announced that its prefilled
syringe for self-injection has received FDA approval for Xolair (omalizumab) in
the U.S. for chronic idiopathic urticaria allergic asthma, and nasal polyps.
The allergy diagnostics & therapeutics
market is moderately competitive, with a strong presence of notable companies
such as Merck & Co., Inc, Thermo Fisher Scientific, Inc., Abbott, and
Pfizer, Inc. These players are undertaking various initiatives to increase
their capabilities, expand their product portfolios, and improve their
competencies.
List of Key Players in Allergy Diagnostics
And Therapeutics Market
·
R-Biopharm AG
·
Thermo Fisher Scientific, Inc.
·
DASIT Group SPA
·
EUROIMMUN Medizinische Labordiagnostika AG
(PerkinElmer, Inc.)
·
AESKU.GROUP GmbH
·
bioMérieux
·
Siemens Healthcare GmbH
·
Stallergenes Greer
·
HYCOR Biomedical
·
Minaris Medical America, Inc.
·
Omega Diagnostics Group PLC
·
Lincoln Diagnostics, Inc.
·
HOB Biotech Group Corp., Ltd.
·
Danaher
·
Alcon
·
AbbVie, Inc.
·
Sanofi
·
Allergy Therapeutics
·
Pfizer, Inc.
·
Teva Pharmaceutical Industries Ltd.
·
GSK plc
·
Sun Pharmaceutical Industries Ltd
·
F. Hoffmann-La Roche Ltd.
·
Merck & Co., Inc.
·
Astellas Pharma Inc.
·
Epigenomics AG
Request a
free sample copy or view report summary: Allergy
Diagnostics And Therapeutics Market Report
Allergy Diagnostics And
Therapeutics Market Report Highlights
·
The consumables product segment held the
largest share in the allergy diagnostics & therapeutics market in 2022. The
advent of products that include the MeDALL allergen-chip, which is linked with
increased sensitivity, precision, and faster detection, is anticipated to
encourage market growth
·
The drug allergies segment is expected to
advance lucratively due to the increasing availability of treatment options and
growing awareness about drug allergies among patients
·
In vitro tests accounted for the highest share
in 2022 due to an increase in the incidence of allergies such as asthma,
rhinitis, & allergic conjunctivitis, and a rise in demand for allergy
testing globally
·
Epinephrine dominated the drug class
segment in 2022. The introduction of cost-effective epinephrine autoinjectors
by key companies is expected to significantly augment market growth
·
North America dominated the allergy
diagnostics & therapeutics market in 2022, due to an increase in
understanding of the high potential associated with allergy drugs. This has
driven U.S.-based firms to make considerable investments in the development of
these drugs
·
Asia Pacific is expected to witness
considerable growth in the future owing to the rising incidences of asthma,
chronic cough, and food allergies, among others, in the region
Allergy Diagnostics And
Therapeutics Market Segmentation
Grand View Research has segmented the
global allergy diagnostics & therapeutics market report on the basis of
type, allergen type, test type, and region:
Allergy Diagnostics And Therapeutics
Type Outlook (Revenue, USD Million, 2018 - 2030)
·
Diagnostics
o Instruments
o Consumables
o Services
·
Therapeutics
o Antihistamines
o Decongestants
o Corticosteroids
o Mast Cell Stabilizers
o Leukotriene Inhibitors
o Nasal Anti-cholinergic
o Immuno-modulators
o Epinephrine
o Immunotherapy
Allergy Diagnostics And Therapeutics
Allergen Type Outlook (Revenue, USD Million, 2018 - 2030)
·
Food
o Dairy Products
o Poultry Product
o Tree Nuts
o Peanuts
o Shellfish
o Wheat
o Soys
o Other Food Allergens
·
Inhaled
·
Drug
·
Other Allergens
Allergy Diagnostics And Therapeutics Test
Type Outlook (Revenue, USD Million, 2018 - 2030)
·
In vivo Test
o Skin Prick Test
o Intradermal Test
o Patch Test
·
In vitro Test
Allergy Diagnostics And Therapeutics
Regional Outlook (Revenue, USD Million, 2018- 2030)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
·
Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
·
Latin America
o Brazil
o Mexico
o Argentina
·
Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment